APA
ADMA icon

American Portfolios Advisors’s ADMA Biologics ADMA Stock Holding History

American Portfolios Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$2.43K Hold
1,000
– – ﹤0.01% 3064
2022
Q2 		$1.98K Hold
1,000
– – ﹤0.01% 3137
2022
Q1 		$1.83K Buy
+1,000
New +$1.56K ﹤0.01% 3247

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

American Portfolios Advisors's ADMA Position: Q3 2022 in Review

American Portfolios Advisors held its ADMA Biologics (ADMA) position steady in Q3 2022 at 1,000 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

American Portfolios Advisors first reported a position in ADMA in Q1 2022 and has held it in 3 quarters since. 130 funds tracked by Wall St. Rank hold ADMA as of Q3 2022.

  • American Portfolios Advisors held 1,000 shares of ADMA Biologics worth $2.43K as of Q3 2022.
  • American Portfolios Advisors left its ADMA Biologics share count unchanged in Q3 2022.
  • ADMA Biologics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #3064 holding.
  • American Portfolios Advisors first reported a position in ADMA Biologics in Q1 2022 and has held it in 3 quarters since.
  • 130 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.